Financial Performance - Third quarter 2024 net revenue was $10.6 million, a decrease from $12.3 million in the same quarter of 2023, with expectations of at least $25 million in net revenue for the fourth quarter[10]. - Product revenue for Q3 2024 was $10,612,000, a decrease from $12,281,000 in Q3 2023, representing a decline of 13.6%[22]. - Total revenues for the nine months ended September 30, 2024, were $45,286,000, compared to $21,663,000 for the same period in 2023, showing an increase of 109.1%[22]. - The net loss for Q3 2024 was $60.8 million, an improvement from a net loss of $87.2 million in Q3 2023[15]. - Net loss for Q3 2024 was $60,808,000, compared to a net loss of $87,232,000 in Q3 2023, indicating an improvement of 30.3%[22]. Expenses - Research and development expenses decreased to $23.2 million in Q3 2024 from $58.5 million in Q3 2023, a reduction of $35.3 million[14]. - Selling, general and administrative expenses were $39.8 million for Q3 2024, down from $40.8 million in Q3 2023, primarily due to reduced employee compensation and commercial expenses[13]. - Total operating expenses for Q3 2024 were $65,750,000, down from $99,272,000 in Q3 2023, a reduction of 33.8%[22]. Cash Position and Assets - The company's cash position was approximately $118.7 million as of September 30, 2024, including $48.0 million in restricted cash[8]. - Cash and cash equivalents decreased to $70,651,000 as of September 30, 2024, from $221,755,000 as of December 31, 2023[23]. - Total assets decreased to $465,056,000 as of September 30, 2024, from $619,161,000 as of December 31, 2023[23]. - Total liabilities increased to $470,842,000 as of September 30, 2024, compared to $424,624,000 as of December 31, 2023[23]. - Total stockholders' equity was negative $5,786,000 as of September 30, 2024, down from $194,537,000 as of December 31, 2023[23]. Patient Starts and Demand - 74 patient starts completed or scheduled in 2024, with 57 patient starts completed to date, including 35 for ZYNTEGLO, 17 for LYFGENIA, and 5 for SKYSONA[1][3]. - The company has scheduled 30 patient starts for 2025, indicating strong commercial demand and supporting the potential for cash flow breakeven[3]. Future Outlook - The company anticipates achieving cash flow break-even in the second half of 2025, assuming approximately 40 drug product deliveries per quarter and securing additional cash resources[10][2]. - The company is presenting updated data on its gene addition programs at the ASH 2024 Annual Meeting, highlighting ongoing research efforts[5][6][7]. Coverage and Market - More than half of U.S. states have affirmed coverage for LYFGENIA, with nearly 50% of Medicaid-insured individuals with sickle cell disease living in states that have completed prior authorization approval[4]. Interest Income - Interest income for Q3 2024 was $1,640,000, compared to $2,454,000 in Q3 2023, a decrease of 33.1%[22]. Gross Margin - Gross margin for Q3 2024 was negative $1,169,000, compared to a positive $3,266,000 in Q3 2023[22].

Bluebird Bio (BLUE) has been beaten down lately with too much selling pressure. While the stock has lost 22.8% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier. Guide to Identifying Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator th ...

Bluebird Bio (BLUE, Financial) experienced a significant drop in its stock price, declining by 5.67%. The shares are currently trading at $0.491, with a trading volume of 3.72 million shares, a turnover rate of 1.92%, and showing a price amplitude of 4.76%.The recent financial report indicates that Bluebird Bio generated $16.10 million in revenue, with a net loss of $81.39 million. The earnings per share (EPS) stand at -$0.42, and the gross profit is reported at -$12.85 million. The price-to-earnings (P/E) ...

Bluebird Bio (BLUE, Financial) stock experienced a notable surge of 5.04% to $0.494 per share. The trading volume reached 6.47552 million shares, resulting in a turnover rate of 3.34% and a volatility of 8.69%.According to the latest financial report, Bluebird Bio posted a revenue of $16.10 million, a net loss of $81.39 million, an earnings per share (EPS) of -$0.42, and a gross profit of -$12.85 million. The company's price-to-earnings (P/E) ratio stands at -0.21.Among the ten institutions that rated the s ...

Financial Performance - The company reported a net loss of $81.4 million and $151.2 million for the three and six months ended June 30, 2024, respectively, with an accumulated deficit of $4.4 billion[138]. - Total revenue for the three months ended June 30, 2024, was $16.1 million, an increase of $9.2 million compared to $6.9 million for the same period in 2023[159]. - Total revenue for the six months ended June 30, 2024, was $34.7 million, compared to $9.3 million for the same period in 2023, an increase of $25.4 million[164]. - The company recorded a net loss of $81.4 million for the three months ended June 30, 2024, compared to a net loss of $62.8 million for the same period in 2023[157]. - The company incurred a net loss of $107.3 million for the six months ended June 30, 2024, compared to a net cash used in operating activities of $140.9 million[175]. Cash and Financing - As of June 30, 2024, the company had cash and cash equivalents of approximately $144.1 million, which is expected to fund operations into the second quarter of 2025, assuming planned cost-saving initiatives are implemented[141]. - As of June 30, 2024, the company had cash and cash equivalents of approximately $144.1 million, down from $221.8 million as of December 31, 2023[170][179]. - The company entered into a five-year term loan facility agreement with Hercules Capital, Inc. for up to $175.0 million, available in four tranches[136]. - The company entered into a Loan Agreement for up to $175.0 million in debt financing in March 2024[174]. - The company reported a net cash provided by financing activities of $58.6 million for the six months ended June 30, 2024, a decrease of $42.9 million compared to the same period in 2023[176]. - The company has $49.2 million in restricted cash as of June 30, 2024, which is unlikely to be released in the near term[171]. Research and Development - The company plans to continue incurring significant research and development expenses as it commercializes ZYNTEGLO, SKYSONA, and LYFGENIA, while also scaling manufacturing capabilities[138][148]. - Research and development expenses decreased to $25.2 million for the three months ended June 30, 2024, from $31.4 million in the same period in 2023, a reduction of $6.3 million[161]. - Research and development expenses for the six months ended June 30, 2024, were $50.2 million, down from $73.0 million in the same period in 2023, a decrease of $22.8 million[168]. - The company expects research and development expenses to decrease as commercial activities increase, particularly with the commercialization of ZYNTEGLO, SKYSONA, and LYFGENIA[170]. Commercialization and Market Focus - The company has received FDA approvals for three gene therapies: ZYNTEGLO, SKYSONA, and LYFGENIA, with LYFGENIA approved in December 2023 for sickle cell disease[131][132]. - The company has withdrawn marketing authorizations for beti-cel and eli-cel in the European Union, focusing its efforts on the U.S. market[133]. - The company anticipates that selling, general, and administrative expenses will continue to increase as commercialization activities for its products expand[145]. - A restructuring action was approved in September 2024, resulting in a workforce reduction of approximately 25%, which is expected to incur charges of $3.3 million to $3.7 million[136][137]. - The company implemented a restructuring in September 2024 to support its commercial focus and reduce cash operating expenses[171]. Product Revenue and Sales - Cost of product revenue for the three months ended June 30, 2024, was $28.9 million, up from $6.7 million in the same period in 2023, primarily due to increased product sales[159]. - Cost of product revenue for the six months ended June 30, 2024, was $54.8 million, up from $12.2 million in the same period in 2023, reflecting increased product sales[165]. - The company sold its first Rare Pediatric Disease Priority Review Voucher (PRV) for net proceeds of $102.0 million in Q4 2022 and its second PRV for net proceeds of $92.9 million in Q1 2023[135]. - The company sold a priority review voucher in the first quarter of 2023 for net proceeds of $92.9 million, received under an FDA program[152]. - The company sold its second priority review voucher (PRV) for aggregate net proceeds of $92.9 million in the first quarter of 2023, but did not have similar proceeds in 2024[173][176]. Future Outlook - Future net product revenues will depend on market demand, manufacturing capabilities, and reimbursement from third-party payers, which could affect the company's financial condition[142].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 __________________________________________________________________ FORM 10-Q __________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ___________________________________________________________________________ FORM 10-K ___________________________________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission ...

bluebird bio, Inc. (NASDAQ:BLUE) Q2 2024 Results Conference Call August 14, 2024 8:00 AM ET Company Participants Courtney O'Leary - Director of Investor Relations Andrew Obenshain - CEO Tom Klima - Chief Commercial and Operating Officer James Sterling - CFO Conference Call Participants Jack Allen - Baird Eric Joseph - JPMorgan Gena Wang - Barclays Jeff Hung - Morgan Stanley Luca Issi - RBC Capital Markets Sami Corwin - William Blair Operator Thank you for standing by. My name is Ken and I will be your confe ...

Exhibit 4.1 In accordance with Instruction 2 to Item 601 of Regulation S-K, below is a schedule setting forth details in which the omitted executed warrants differ from the form of warrant that follows: Warrantholder Hercules Capital, Inc. Hercules Private Credit Fund 1 L.P. Hercules Private Global Venture Growth Fund I L.P. THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR ANY STATE SECURITIES LAWS, AND MAY NOT BE ...

TORONTO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Clear Blue Technologies International Inc. (TSXV: CBLU) (the "Company") is pleased to announce that it has received significant financial support from its stakeholders to provide financial support to the Company as it continues to invest in its AI leadership in Smart Power for Internet of Things, Smart City and Telecom markets around the world. The financing consists of the following transactions: SOFII (Southern Ontario Fund for Investment in Innovation), a previo ...